| EMR |
Report |
Adj Segment EBITA Margin (3Q26) |
BEAT |
pred ~28.0% vs. cons 26.63% |
HIGH |
| EMR |
Report |
Adj EPS Diluted Operating (3Q26) |
BEAT |
pred ~$1.70 vs. cons $1.677 |
MEDIUM |
| EMR |
Report |
Net Sales (3Q26) |
IN-LINE |
pred ~$4.78B vs. cons $4.801B |
MEDIUM |
| EMR |
Guide |
Adj EPS FY2026 (full year) |
UNCHANGED |
guide ~$6.50 mid vs. cons $6.502 |
HIGH |
| EMR |
Guide |
Adj EPS Q4 2026 (implied out-period) |
LOWER |
implied ~$1.80 vs. cons $1.827 |
MEDIUM |
| EMR |
Guide |
Adj Seg EBITA Margin FY2026 |
BETTER |
guide ~28% vs. cons 26.54% |
HIGH |
| EMR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
MEDIUM |
| EMR |
Return |
5-day cumulative residual |
-5.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — Q4 implied cut drives sell-side estimate revisions lower over 5 days |
MEDIUM |